ArticleFrontiers in oncology2026
Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer (BC) is the most commonly diagnosed malignancy among women globally and in India. The human epidermal growth factor receptor 2 (HER2)-positive subtype is associated with aggressive disease and poorer prognosis; however, neoadjuvant therapy combining dual HER2 blockade with chemotherapy has been shown to improve pathological complete response (pCR) rates. This study evaluated the real-world effectiveness of dual HER2 blockade in the Indian setting. Methods: This ambispective, descriptive real-world study was conducted at KIMSHEALTH, Trivandrum, Kerala (1 October 2019-30 April 2025), comprising retrospective (1 October 2019-30 April 2024) and prospective (1 May 2024-30 April 2025) phases. Patients with HER2-positive early BC receiving intravenous (IV) or subcutaneous (SC) pertuzumab and trastuzumab were included. The primary endpoint was pCR. Secondary endpoints included comparison of pCR between the IV and SC groups; assessment of chemotherapy regimen, disease stage, and hormonal status on outcomes; and evaluation of treatment-related toxicities. Results: A total of 74 patients (35: retrospective; 39: prospective) (mean age: 56.8 ± 9.1 years) were included in the study; 52 (70.3%) received SC, and 22 (29.7%) received IV dual HER2 blockade. The overall pCR rate was 51.4% (SC: 44.2%; IV: 68.2%; p=0.06). Tumor stage (p=0.044) and composite clinical stage (tumor, node, and metastasis) (p=0.019) were significantly associated with pCR in the overall population, whereas estrogen receptor (ER) status was not associated with pCR (p=0.064). Multivariate analysis identified the composite clinical stage as an independent predictor of pCR (odds ratio: 0.242; p=0.012). Anemia was the most common toxicity, followed by hepatic toxicity, with comparable safety between the SC and IV groups. Discussion: Neoadjuvant dual HER2 blockade in HER2-positive BC is effective and well tolerated in the Indian real-world setting, with tumor stage and composite clinical stage significantly influencing response, while ER status showed no significant association with pCR. SC and IV dual HER2 blockade demonstrated comparable efficacy and safety outcomes. These findings, which are consistent with historical data, further reinforce the therapeutic advancement from trastuzumab-based therapy to dual HER2 blockade, highlighting its improved effectiveness and clinical importance in the neoadjuvant treatment of HER2-positive BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.